state-of-the-art interfaces to biological systems by
employing novel microfluidic technologies. This enables completely new types
of assays and devices with superior performance characteristics and
robustness. Cellectricon's products address critical bottlenecks in the drug
discovery process and have been adopted by top-reference customers, including
nine of the top ten pharmaceutical companies. In 2007, the company increased
its annual revenue by almost 50%. In 2008-2009 the company is launching two
pioneering large-scale screening platforms developed in close collaboration
with leaders in the pharmaceutical industry. Used in pre-clinical
pharmaceutical development, the Cellaxess(R)HT System enables high throughput
RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug
discovery.
About The Automation Partnership
The Automation Partnership (TAP) is a world leader in the design,
development and implementation of advanced automation systems for the life
sciences research industry. TAP specializes in automation for cell culture,
sample management and advanced screening applications. These range from
multi-million pound large-scale drug discovery facilities to standalone
bench-top products. TAP also offers custom engineering services to customers
requiring unique solutions for complex and challenging research problems.
TAP's customers include the world's top pharmaceutical and biotechnology
companies, key service providers and leading research institutions including:
Amgen, AstraZeneca, ATCC, GlaxoSmithKline, Loughborough University, Max
Planck Institute, Merck, Oxford University, Stem Cell Sciences, UK Biobank
and Wyeth.
Contact Cellectricon:
Jonas Ohlsson, CEO
Phone: +46(0)709-73-47-92
E-mail: jonas.ohlsson@cellectricon.com
Susanne Fagerlund, VP Marketing & Communicat
'/>"/>
SOURCE Cellectricon AB Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion2.
Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology3.
Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System4.
Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership5.
NuVasive to Present at Thomas Weisel Partners Healthcare Conference6.
Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 20077.
GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product8.
ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference9.
Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast10.
SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th11.
NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007